Over 200 COVID-19 trials nearing completion should provide a busy summer of data readouts

Less than three months after COVID-19 reached pandemic status, and five since the virus was sequenced, drug development has reached the point where hundreds of clinical trials will soon read out. With a pile of repurposed agents, a handful of novel vaccines and the first SARS-CoV-2 neutralizing mAb on deck, the winnowing of mechanisms and modalities may soon begin.

A look at the compounds and therapeutic mechanisms in these studies hints at the biological questions that could be start to be answered in the near term, while an assessment of trial sizes, comparators and phases can help separate impending signal from noise...